OBJECTIVES: To compare diabetes management in adults between England and the United States, particularly focusing on the impact of a universal access health insurance system. DESIGN: Analysis of the nationally-representative surveys Health Survey of England, 2003 (unweighted n =14 057) and the National Health and Nutrition Examination Survey, 2001-2002 (unweighted n =5411). SETTING AND PARTICIPANTS: Adults 20-64 years of age; individuals >65. MAIN OUTCOME MEASURES: Glycaemic, lipid and blood pressure control and medication use among individuals with previously diagnosed diabetes. RESULTS: Among those aged 20-64 the prevalence of diagnosed diabetes was lower in England (2.7%) than in the USA (5.0%). The proportion with diabetes receiving treatment was similar for the two countries. However, the mean HbA1c in England was 7.6%: in the USA it was 7.5% for those with insurance and 8.6% for those without insurance. The proportion of individuals on ACE inhibitors in England was 39%: in USA it was 39% for those with insurance, and 14% for those without. CONCLUSIONS: Individuals in a healthcare system providing universal access have better managed diabetes than those in a market based system once one accounts for insurance.
OBJECTIVES: To compare diabetes management in adults between England and the United States, particularly focusing on the impact of a universal access health insurance system. DESIGN: Analysis of the nationally-representative surveys Health Survey of England, 2003 (unweighted n =14 057) and the National Health and Nutrition Examination Survey, 2001-2002 (unweighted n =5411). SETTING AND PARTICIPANTS: Adults 20-64 years of age; individuals >65. MAIN OUTCOME MEASURES: Glycaemic, lipid and blood pressure control and medication use among individuals with previously diagnosed diabetes. RESULTS: Among those aged 20-64 the prevalence of diagnosed diabetes was lower in England (2.7%) than in the USA (5.0%). The proportion with diabetes receiving treatment was similar for the two countries. However, the mean HbA1c in England was 7.6%: in the USA it was 7.5% for those with insurance and 8.6% for those without insurance. The proportion of individuals on ACE inhibitors in England was 39%: in USA it was 39% for those with insurance, and 14% for those without. CONCLUSIONS: Individuals in a healthcare system providing universal access have better managed diabetes than those in a market based system once one accounts for insurance.
Authors: Arch G Mainous; Richelle J Koopman; James M Gill; Richard Baker; William S Pearson Journal: Am J Public Health Date: 2004-01 Impact factor: 9.308
Authors: Emmanuela Gakidou; Leslie Mallinger; Jesse Abbott-Klafter; Ramiro Guerrero; Salvador Villalpando; Ruy Lopez Ridaura; Wichai Aekplakorn; Mohsen Naghavi; Stephen Lim; Rafael Lozano; Christopher J L Murray Journal: Bull World Health Organ Date: 2010-11-22 Impact factor: 9.408
Authors: Xing-Wei Wong; J Geoffrey Chase; Christopher E Hann; Thomas F Lotz; Jessica Lin; Aaron J Le Compte; Geoffrey M Shaw Journal: J Diabetes Sci Technol Date: 2008-05
Authors: Jesse C Crosson; Pamela A Ohman-Strickland; Stephen Campbell; Robert L Phillips; Martin O Roland; Evangelos Kontopantelis; Andrew Bazemore; Bijal Balasubramanian; Benjamin F Crabtree Journal: Fam Pract Date: 2009-09-11 Impact factor: 2.267
Authors: Xuanping Zhang; Kai McKeever Bullard; Edward W Gregg; Gloria L Beckles; Desmond E Williams; Lawrence E Barker; Ann L Albright; Giuseppina Imperatore Journal: Diabetes Care Date: 2012-04-20 Impact factor: 19.112
Authors: Ben Boursi; Brian Finkelman; Bruce J Giantonio; Kevin Haynes; Anil K Rustgi; Andrew D Rhim; Ronac Mamtani; Yu-Xiao Yang Journal: Eur J Gastroenterol Hepatol Date: 2022-01-01 Impact factor: 2.586